[
  {
    "objectID": "Workpackage1_singledrug.html",
    "href": "Workpackage1_singledrug.html",
    "title": "Workpackage 1-Single Drug",
    "section": "",
    "text": "In this package we will establish the quantitative relationship of Tpos and KPC-carbapenemase producing Klebsiella pneumoniae inoculum in blood culture bottles. \nThe methods for the assay are a modification of those originally proposed by Kaltsas et al.1 Detailed procedures can be found at this link. Methodology for preparing the test inoculum was adapted from CLSI M21A and M26A guidelines.\n\nBriefly, tubes containing 1.8 mL of pooled healthy human serum are inoculated with 0.2 mL of a series of ten-fold dilutions (5x101 to 5x107 CFU/mL) of the standardised inoculum of each test indicator strains.\nThe sera were are then transferred into BacT⁄ALERT bottles without antibiotic inactivating matrix (Biomérieux Inc) for aerobic incubation for 24 hours and monitored for time to positivity.\nTpos results were used to establish preliminary assay quality control ranges by testing in triplicate for five KPC-carbapenemase producing K. pneumoniae strains (KPC A, B and C strains; NDM, and VIM producing strains) and a reference K. pneumoniae ATCC strain producing ESBL enzyme only. More detailed information on the isolates can be found on the Protocols section.\nWe also compared how Tpos results change if the organism suspension prepared in phosphate buffered saline (PBS-0.9%) versus pooled human serum (serum).\n\n\n\n\nThe relationship between Tpos and the K. pneumoniae inoculum is shown in ?@fig-1 a linear relationship was observed from approximately 101-108 K. pneumoniae CFU/mL and a Tpos measured from 10.5 hours-4.5 hours over the tested inoculum range, with R2 of 0.92-0.94. The linear relationship of Tpos versus inoculum was consistent if the inoculum was prepared in PBS or pooled human serum as shown in Table 1.\n\n\n\n\n\n\nNote\n\n\n\nIn the paper by Kaltsas et al.1 the reported inoculum was the inoculum introduced in to the bloodculture bottle, 30-40 mL of growth media (depending on the manufacturer).\nTherefore we have followed this precedent of reporting the inoculum introduced into each bottle. Therefore, this does not represent the final test inoculum that need to account for the total 42 mL volume in each bloodculture bottle.\nAll experiments were performed using bloodculture bottles without antibiotic inactivating matrix\n\n\n\n\n\n\nCode\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nwp1 &lt;- read.csv(\"~/Desktop/ACUTEWEBSITE/wp1a.csv\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfig1 &lt;-ggplot(wp1, aes(x=inoculum, y=tpos, color=isolates, shape=diluent, fill=isolates)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE)\nfig1\nfig1 + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\n\n\n\nFigure 1: Relationship of time-to-positivity (Tpos) versus test inoculum\n\n\n\n\n\n\n\n\n\n\n\nFigure 2: Relationship of time-to-positivity (Tpos) versus test inoculum\n\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nwp1 &lt;- read.csv(\"~/Desktop/ACUTEWEBSITE/wp1a.csv\")\ndf &lt;- data.frame (wp1)\ntable1&lt;-lm_table(df, log(inoculum) ~ tpos, \"diluent\")\nkbl(table1)%&gt;%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 1: Effect of inoculum diluent on Tpos\n\n\n\n\n\n\n\ndiluent\nb0\nb1\nRsqr\nRsqr_adj\nStd.Error\n\n\n\n\npbs\n32.05074\n-2.564975\n0.9343070\n0.9336227\n1.110872\n\n\nserum\n33.02361\n-2.840223\n0.9231703\n0.9216023\n1.210130\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCode\n## import raw data from .xlsx file\nlibrary (readxl)\necoliatcc_inoc &lt;- read_excel(\"datasets_single/ecoliatcc_inoculum.xlsx\")\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfigecoli &lt;-ggplot(ecoliatcc_inoc, aes(x=inoculum, y=tpos)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nfigecoli + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\n\n\n\nFigure 3: Relationship of time-to-positivity (Tpos) versus test inoculum\n\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nlibrary (readxl)\necoliatcc_inoc &lt;- read_excel(\"datasets_single/ecoliatcc_inoculum.xlsx\")\ndfecoli &lt;- data.frame (ecoliatcc_inoc)\ntable1&lt;-lm_table(dfecoli, log(inoculum) ~ tpos, \"diluent\")\nkbl(table1)%&gt;%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 2: Effect of inoculum diluent on Tpos\n\n\n\n\n\n\n\ndiluent\nb0\nb1\nRsqr\nRsqr_adj\nStd.Error\n\n\n\n\npbs\n29.52142\n-2.295468\n0.9933486\n0.9929985\n0.3948541\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCode\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nlibrary (readxl)\nabaumani &lt;- read_excel(\"abaum_pbs.xlsx\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfig1ab &lt;-ggplot(abaumani, aes(x=inoculum, y=tpos)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nfig1ab + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\n\n\n\nFigure 4: Relationship of time-to-positivity (Tpos) versus test inoculum for Acinetobacter baumanii\n\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nlibrary (readxl)\nabaumani &lt;- read_excel(\"abaum_pbs.xlsx\")\ndf &lt;- data.frame (abaumani)\ntable1&lt;-lm_table(df, log(inoculum) ~ tpos, \"diluent\")\nkbl(table1)%&gt;%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 3: Effect of inoculum diluent on Tpos for Acinetobacter baumanii\n\n\n\n\n\n\n\ndiluent\nb0\nb1\nRsqr\nRsqr_adj\nStd.Error\n\n\n\n\npbs\n28.35235\n-2.158901\n0.9924317\n0.9921406\n0.4157561\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCode\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nlibrary (readxl)\npseudo &lt;- read_excel(\"pseudo_pbs.xlsx\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfig2f &lt;-ggplot(pseudo, aes(x=inoculum, y=tpos, color=isolates, fill=isolates)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nfig2f + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\n\n\n\nFigure 5: Relationship of time-to-positivity (Tpos) versus test inoculum for Pseudomonas aeruginosa\n\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nlibrary (readxl)\npseudo &lt;- read_excel(\"pseudo_pbs.xlsx\")\ndf_pseudo &lt;- data.frame (pseudo)\ntable2&lt;-lm_table(df_pseudo, log(inoculum) ~ tpos, \"diluent\")\nkbl(table2)%&gt;%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 4: Effect of inoculum diluent on Tpos for pseudomonas aeruginosa\n\n\n\n\n\n\n\ndiluent\nb0\nb1\nRsqr\nRsqr_adj\nStd.Error\n\n\n\n\npbs\n26.16852\n-1.465734\n0.9842056\n0.9838108\n0.59305\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThese data confirm that Tpos exhibits a wide dynamic range and reproducible relationship as a surrogate indicator for viable CFU/mL.",
    "crumbs": [
      "Workpackage 1-Single Drug"
    ]
  },
  {
    "objectID": "Workpackage1_singledrug.html#workpackage-1a-quantitative-relationship-of-tpos-with-bacterial-inoculum",
    "href": "Workpackage1_singledrug.html#workpackage-1a-quantitative-relationship-of-tpos-with-bacterial-inoculum",
    "title": "Workpackage 1-Single Drug",
    "section": "",
    "text": "In this package we will establish the quantitative relationship of Tpos and KPC-carbapenemase producing Klebsiella pneumoniae inoculum in blood culture bottles. \nThe methods for the assay are a modification of those originally proposed by Kaltsas et al.1 Detailed procedures can be found at this link. Methodology for preparing the test inoculum was adapted from CLSI M21A and M26A guidelines.\n\nBriefly, tubes containing 1.8 mL of pooled healthy human serum are inoculated with 0.2 mL of a series of ten-fold dilutions (5x101 to 5x107 CFU/mL) of the standardised inoculum of each test indicator strains.\nThe sera were are then transferred into BacT⁄ALERT bottles without antibiotic inactivating matrix (Biomérieux Inc) for aerobic incubation for 24 hours and monitored for time to positivity.\nTpos results were used to establish preliminary assay quality control ranges by testing in triplicate for five KPC-carbapenemase producing K. pneumoniae strains (KPC A, B and C strains; NDM, and VIM producing strains) and a reference K. pneumoniae ATCC strain producing ESBL enzyme only. More detailed information on the isolates can be found on the Protocols section.\nWe also compared how Tpos results change if the organism suspension prepared in phosphate buffered saline (PBS-0.9%) versus pooled human serum (serum).\n\n\n\n\nThe relationship between Tpos and the K. pneumoniae inoculum is shown in ?@fig-1 a linear relationship was observed from approximately 101-108 K. pneumoniae CFU/mL and a Tpos measured from 10.5 hours-4.5 hours over the tested inoculum range, with R2 of 0.92-0.94. The linear relationship of Tpos versus inoculum was consistent if the inoculum was prepared in PBS or pooled human serum as shown in Table 1.\n\n\n\n\n\n\nNote\n\n\n\nIn the paper by Kaltsas et al.1 the reported inoculum was the inoculum introduced in to the bloodculture bottle, 30-40 mL of growth media (depending on the manufacturer).\nTherefore we have followed this precedent of reporting the inoculum introduced into each bottle. Therefore, this does not represent the final test inoculum that need to account for the total 42 mL volume in each bloodculture bottle.\nAll experiments were performed using bloodculture bottles without antibiotic inactivating matrix\n\n\n\n\n\n\nCode\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nwp1 &lt;- read.csv(\"~/Desktop/ACUTEWEBSITE/wp1a.csv\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfig1 &lt;-ggplot(wp1, aes(x=inoculum, y=tpos, color=isolates, shape=diluent, fill=isolates)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE)\nfig1\nfig1 + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\n\n\n\nFigure 1: Relationship of time-to-positivity (Tpos) versus test inoculum\n\n\n\n\n\n\n\n\n\n\n\nFigure 2: Relationship of time-to-positivity (Tpos) versus test inoculum\n\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nwp1 &lt;- read.csv(\"~/Desktop/ACUTEWEBSITE/wp1a.csv\")\ndf &lt;- data.frame (wp1)\ntable1&lt;-lm_table(df, log(inoculum) ~ tpos, \"diluent\")\nkbl(table1)%&gt;%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 1: Effect of inoculum diluent on Tpos\n\n\n\n\n\n\n\ndiluent\nb0\nb1\nRsqr\nRsqr_adj\nStd.Error\n\n\n\n\npbs\n32.05074\n-2.564975\n0.9343070\n0.9336227\n1.110872\n\n\nserum\n33.02361\n-2.840223\n0.9231703\n0.9216023\n1.210130\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCode\n## import raw data from .xlsx file\nlibrary (readxl)\necoliatcc_inoc &lt;- read_excel(\"datasets_single/ecoliatcc_inoculum.xlsx\")\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfigecoli &lt;-ggplot(ecoliatcc_inoc, aes(x=inoculum, y=tpos)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nfigecoli + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\n\n\n\nFigure 3: Relationship of time-to-positivity (Tpos) versus test inoculum\n\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nlibrary (readxl)\necoliatcc_inoc &lt;- read_excel(\"datasets_single/ecoliatcc_inoculum.xlsx\")\ndfecoli &lt;- data.frame (ecoliatcc_inoc)\ntable1&lt;-lm_table(dfecoli, log(inoculum) ~ tpos, \"diluent\")\nkbl(table1)%&gt;%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 2: Effect of inoculum diluent on Tpos\n\n\n\n\n\n\n\ndiluent\nb0\nb1\nRsqr\nRsqr_adj\nStd.Error\n\n\n\n\npbs\n29.52142\n-2.295468\n0.9933486\n0.9929985\n0.3948541\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCode\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nlibrary (readxl)\nabaumani &lt;- read_excel(\"abaum_pbs.xlsx\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfig1ab &lt;-ggplot(abaumani, aes(x=inoculum, y=tpos)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nfig1ab + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\n\n\n\nFigure 4: Relationship of time-to-positivity (Tpos) versus test inoculum for Acinetobacter baumanii\n\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nlibrary (readxl)\nabaumani &lt;- read_excel(\"abaum_pbs.xlsx\")\ndf &lt;- data.frame (abaumani)\ntable1&lt;-lm_table(df, log(inoculum) ~ tpos, \"diluent\")\nkbl(table1)%&gt;%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 3: Effect of inoculum diluent on Tpos for Acinetobacter baumanii\n\n\n\n\n\n\n\ndiluent\nb0\nb1\nRsqr\nRsqr_adj\nStd.Error\n\n\n\n\npbs\n28.35235\n-2.158901\n0.9924317\n0.9921406\n0.4157561\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCode\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nlibrary (readxl)\npseudo &lt;- read_excel(\"pseudo_pbs.xlsx\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfig2f &lt;-ggplot(pseudo, aes(x=inoculum, y=tpos, color=isolates, fill=isolates)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nfig2f + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\n\n\n\nFigure 5: Relationship of time-to-positivity (Tpos) versus test inoculum for Pseudomonas aeruginosa\n\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nlibrary (readxl)\npseudo &lt;- read_excel(\"pseudo_pbs.xlsx\")\ndf_pseudo &lt;- data.frame (pseudo)\ntable2&lt;-lm_table(df_pseudo, log(inoculum) ~ tpos, \"diluent\")\nkbl(table2)%&gt;%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 4: Effect of inoculum diluent on Tpos for pseudomonas aeruginosa\n\n\n\n\n\n\n\ndiluent\nb0\nb1\nRsqr\nRsqr_adj\nStd.Error\n\n\n\n\npbs\n26.16852\n-1.465734\n0.9842056\n0.9838108\n0.59305\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThese data confirm that Tpos exhibits a wide dynamic range and reproducible relationship as a surrogate indicator for viable CFU/mL.",
    "crumbs": [
      "Workpackage 1-Single Drug"
    ]
  },
  {
    "objectID": "Workpackage1_singledrug.html#workpackage-1b-effect-of-antibiotic-exposure-on-tpos",
    "href": "Workpackage1_singledrug.html#workpackage-1b-effect-of-antibiotic-exposure-on-tpos",
    "title": "Workpackage 1-Single Drug",
    "section": "WORKPACKAGE 1B: EFFECT OF ANTIBIOTIC EXPOSURE ON TPOS",
    "text": "WORKPACKAGE 1B: EFFECT OF ANTIBIOTIC EXPOSURE ON TPOS\n\nMETHODS\nThis workpackage explores how cantibiotic concentrations alters Tpos for a standard (1x104 CFU/mL) inoculum of Enterobacterales.\n\n\nRESULTS\n\n\n\nCEFTAZIDIME-AVIBACTAM\n\nPreliminary experiments KPC and NDM isolates\nAs shown in Figure 6, a marked increased in the Tpos for KPC_B from &lt; 10 hrs to &gt; 24 hrs when CAZ/AVI concentrations surpassed 1 mg/L. In contrast, the negative control KPC_NDM strain exhibited consistent Tpos &lt; 10hr at all test concentrations with lack of antimicrobial activity. Trends in Tpos relative to antibiotic exposure were fitted by Loess.\n\n\nCode\nlibrary (ggplot2)\ntheme_set(theme_bw())\nceftaz &lt;- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_single/ceftazidime.csv\")\nggplot(ceftaz, aes(x=conc_s, y=tpos, color=isolate, shape=isolate)) + \n  geom_point(size=4, alpha = 0.7) + \n  geom_smooth(aes(linetype=isolate), method= loess, color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE ) +\nscale_x_log10(name=\"CAZ/AVI conc, mg/L\") +\nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,25)) \n\n\n\n\n\n\n\n\nFigure 6: Effect of ceftazidime/aviactam concentrations on Tpos of K. pneumoniae\n\n\n\n\n\nIsolate | Carbapenemase enzyme | Ceftazidime/avibactam Etest MIC (mg/L) |\n&lt;&lt;&lt;&lt;&lt;&lt;&lt; HEAD |————————|——————-|——————————| ======= |————————|——————|——————————| &gt;&gt;&gt;&gt;&gt;&gt;&gt; a72d8bf8db747dca544fb670c6a5f63b1b274185 | Klebsiella pneumoniae KPC- B | KPC-3 | 1 | | Klebsiella pneumoniae NDM | NDM-2 | &gt;64 |\n: Isolates used for testing {#tbl-table2}\n\n\n\n\nK. pneumoniae ATCC 700603 (MIC 0.75 mg/L) powder 4:1\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_7a &lt;- read_excel(\"datasets_single/kpatcc_caz_avi_powder4-1.xlsx\")\nfit_atcc &lt;- drda(tpos ~ ctz_s, data=caz_avi_7a, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit_atcc, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 7: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_7a &lt;- read_excel(\"datasets_single/kpatcc_caz_avi_powder4-1.xlsx\")\nfit_atcc &lt;- drda(tpos ~ ctz_s, data=caz_avi_7a, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit_atcc, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 5: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n23.87874\n19.31716\n28.44033\n\n\n0.25\n26.93812\n24.06902\n29.80723\n\n\n0.5\n30.38948\n29.11007\n31.66888\n\n\n0.75\n34.28302\n31.38838\n37.17767\n\n\n0.9\n38.67541\n33.84814\n43.50268\n\n\n0.95\n41.98020\n33.98412\n49.97627\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nK. pneumoniae ATCC 700603 (MIC 0.75 mg/L) fixed 4 mg/L\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_7b &lt;- read_excel(\"datasets_single/kpatcc_caz_avi_powderfix4.xlsx\")\nfit_atcc2 &lt;- drda(tpos ~ ctz_s, data=caz_avi_7b, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit_atcc2, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 8: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_7a &lt;- read_excel(\"datasets_single/kpatcc_caz_avi_powderfix4.xlsx\")\nfit7a &lt;- drda(tpos ~ ctz_s, data=caz_avi_7a, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit7a, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 6: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n8.099087\n7.038485\n9.159689\n\n\n0.25\n9.235833\n8.728989\n9.742676\n\n\n0.5\n10.532127\n10.149119\n10.915134\n\n\n0.75\n12.010361\n10.856802\n13.163921\n\n\n0.9\n13.696074\n11.685276\n15.706872\n\n\n0.95\n14.975851\n12.415855\n17.535846\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC B (MIC 1 mg/L) commercial\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_4 &lt;- read_excel(\"datasets_single/kpcb_caz_avi_com.xlsx\")\nfit4 &lt;- drda(tpos ~ ctz_s, data=caz_avi_4, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit4, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 9: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_4 &lt;- read_excel(\"datasets_single/kpcb_caz_avi_com.xlsx\")\nfit4 &lt;- drda(tpos ~ ctz_s, data=caz_avi_4, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit4, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 7: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n73.66731\n71.92413\n75.41048\n\n\n0.25\n78.61720\n77.51043\n79.72397\n\n\n0.5\n83.89969\n83.05534\n84.74404\n\n\n0.75\n89.53712\n88.10788\n90.96636\n\n\n0.9\n95.55335\n93.12523\n97.98147\n\n\n0.95\n99.87460\n96.42020\n103.32901\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC B (MIC 1 mg/L) powder 4:1\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_6 &lt;- read_excel(\"datasets_single/kpcb_caz_avi_powder_4-1.xlsx\")\nfit6 &lt;- drda(tpos ~ ctz_s, data=caz_avi_6, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit6, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 10: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_6 &lt;- read_excel(\"datasets_single/kpcb_caz_avi_powder_4-1.xlsx\")\nfit6 &lt;- drda(tpos ~ ctz_s, data=caz_avi_6, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit6, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 8: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n68.88793\n61.14631\n76.62954\n\n\n0.25\n75.52374\n71.50425\n79.54322\n\n\n0.5\n82.79876\n79.85671\n85.74080\n\n\n0.75\n90.77456\n83.70890\n97.84023\n\n\n0.9\n99.51866\n86.97415\n112.06317\n\n\n0.95\n105.94237\n88.43755\n123.44720\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC A (MIC 2 mg/L) commercial\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concencentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_7 &lt;- read_excel(\"datasets_single/kpca_caz_avi_com.xlsx\")\nfit7 &lt;- drda(tpos ~ ctz_s, data=caz_avi_7, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit7, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 11: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parametersestiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_7 &lt;- read_excel(\"datasets_single/kpca_caz_avi_com.xlsx\")\nfit7 &lt;- drda(tpos ~ ctz_s, data=caz_avi_7, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit7, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 9: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n143.5857\n138.9952\n148.1763\n\n\n0.25\n154.0912\n151.7888\n156.3936\n\n\n0.5\n165.3653\n163.4974\n167.2333\n\n\n0.75\n177.4643\n172.9862\n181.9424\n\n\n0.9\n190.4485\n183.1369\n197.7601\n\n\n0.95\n199.8183\n190.5343\n209.1023\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC A (MIC 2 mg/L) powder 4:1\n\n\nCode\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_8 &lt;- read_excel(\"datasets_single/kpca_caz_avi_powder_4-1.xlsx\")\nfit8 &lt;- drda(tpos ~ ctz_s, data=caz_avi_8, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit8, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 12: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parametersestiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_8 &lt;- read_excel(\"datasets_single/kpca_caz_avi_powder_4-1.xlsx\")\nfit8 &lt;- drda(tpos ~ ctz_s, data=caz_avi_8, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit8, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 10: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n125.7716\n114.3869\n137.1562\n\n\n0.25\n143.8460\n136.1835\n151.5085\n\n\n0.5\n164.5179\n158.8981\n170.1377\n\n\n0.75\n188.1605\n179.1859\n197.1350\n\n\n0.9\n215.2007\n197.7571\n232.6444\n\n\n0.95\n235.7798\n202.9734\n268.5861\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC A (MIC 2 mg/L) fixed 4 mg/L\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_9 &lt;- read_excel(\"datasets_single/kpca_caz_avi_powder_fix4.xlsx\")\nfit9 &lt;- drda(tpos ~ ctz_s, data=caz_avi_9, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit9, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 13: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_9 &lt;- read_excel(\"datasets_single/kpca_caz_avi_powder_fix4.xlsx\")\nfit9 &lt;- drda(tpos ~ ctz_s, data=caz_avi_9, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit9, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 11: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n26.02302\n22.05197\n29.99406\n\n\n0.25\n37.21041\n34.05205\n40.36876\n\n\n0.5\n53.20729\n50.04995\n56.36463\n\n\n0.75\n76.08130\n70.56354\n81.59905\n\n\n0.9\n108.78892\n81.37114\n136.20669\n\n\n0.95\n138.74444\n47.74622\n229.74266\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC B (MIC 1 mg/L) fixed 4 mg/L\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_10 &lt;- read_excel(\"datasets_single/kpcb_caz_avi_powder_fix4.xlsx\")\nfit10&lt;- drda(tpos ~ ctz_s, data=caz_avi_10, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit10, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 14: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameters estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_10 &lt;- read_excel(\"datasets_single/kpcb_caz_avi_powder_fix4.xlsx\")\nfit10 &lt;- drda(tpos ~ ctz_s, data=caz_avi_10, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit10, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 12: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n21.16519\n15.15120\n27.17918\n\n\n0.25\n27.06283\n22.30567\n31.81998\n\n\n0.5\n34.60383\n31.40317\n37.80449\n\n\n0.75\n44.24612\n39.07653\n49.41571\n\n\n0.9\n56.57521\n43.63228\n69.51813\n\n\n0.95\n66.87013\n38.60827\n95.13199\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC B (MIC 1 mg/L) high inoculum\nWe examined how the relationship of Tpos vs. ceftazidime/avibactam concentrations changes when tested against a higher inoculum (1x107 CFU/mL). The same methodology as described above was used for testing. As shown in Figure 15 and Table 13 the EC50 and EC90 were marginally higher when tested at the higher inoculum with a more shallow dose-response relationship.\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_5 &lt;- read_excel(\"datasets_single/kpcb_caz_avi_com_hinoc.xlsx\")\nfithinc &lt;- drda(tpos ~ ctz_s, data=caz_avi_5, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fithinc, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 15: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against a high-inoculum\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_5 &lt;- read_excel(\"datasets_single/kpcb_caz_avi_com_hinoc.xlsx\")\nfithinc &lt;- drda(tpos ~ ctz_s, data=caz_avi_5, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fithinc, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 13: Pharmacodynamic estimates for a high-inoculum\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n82.08148\n71.35951\n92.80344\n\n\n0.25\n117.28496\n109.48524\n125.08468\n\n\n0.5\n167.58667\n159.06133\n176.11201\n\n\n0.75\n239.46201\n222.24533\n256.67869\n\n\n0.9\n342.16357\n290.42168\n393.90546\n\n\n0.95\n436.16833\n240.82684\n631.50983\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC Catania (MIC 16 mg/L) powder 4:1\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_catan &lt;- read_excel(\"datasets_single/kpccatania_caz_avi_powder_4-1.xlsx\")\nfitcat &lt;- drda(tpos ~ ctz_s, data=caz_avi_catan, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitcat, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 16: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against a resistant strain\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_5 &lt;- read_excel(\"datasets_single/kpccatania_caz_avi_powder_4-1.xlsx\")\nfitcat &lt;- drda(tpos ~ ctz_s, data=caz_avi_catan, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fitcat, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 14: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n357.0678\n344.5988\n369.5368\n\n\n0.25\n399.4416\n391.4077\n407.4755\n\n\n0.5\n446.8440\n438.8360\n454.8519\n\n\n0.75\n499.8716\n486.9293\n512.8140\n\n\n0.9\n559.1922\n538.6586\n579.7258\n\n\n0.95\n603.5119\n566.2421\n640.7818\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC Catania (MIC 16 mg/L) fixed 4 mg/L\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_5 &lt;- read_excel(\"datasets_single/kpccatania_caz_avi_powderfix.xlsx\")\nfitcat5 &lt;- drda(tpos ~ ctz_s, data=caz_avi_5, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitcat5, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 17: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against a high-inoculum\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_5 &lt;- read_excel(\"datasets_single/kpccatania_caz_avi_powderfix.xlsx\")\nfit5 &lt;- drda(tpos ~ ctz_s, data=caz_avi_5, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit5, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 15: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n227.1879\n181.0095\n273.3664\n\n\n0.25\n292.7908\n255.0843\n330.4973\n\n\n0.5\n377.3372\n356.2659\n398.4084\n\n\n0.75\n486.2972\n454.9664\n517.6279\n\n\n0.9\n626.7205\n552.7132\n700.7278\n\n\n0.95\n744.7437\n610.2525\n879.2349\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC K. pneumoniae KPRAD (MIC 0.5 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_kprad &lt;- read_excel(\"datasets_single/kp_PRAD_caz_avi_powder4-1.xlsx\")\nfitkprad &lt;- drda(tpos ~ ctz_s, data=caz_avi_kprad, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitkprad, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 18: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against KPC- producing K. pneumoniae\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_kprad &lt;- read_excel(\"datasets_single/kp_PRAD_caz_avi_powder4-1.xlsx\")\nfitkprad &lt;- drda(tpos ~ ctz_s, data=caz_avi_kprad, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fitkprad, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 16: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n45.60828\n44.00945\n47.20710\n\n\n0.25\n48.96778\n47.95219\n49.98337\n\n\n0.5\n52.57475\n51.68561\n53.46388\n\n\n0.75\n56.44741\n54.94883\n57.94598\n\n\n0.9\n60.60532\n58.19775\n63.01290\n\n\n0.95\n63.60696\n59.97950\n67.23441\n\n\n\n\n\n\n\n\n\n\n\n\n\nK. pneumoniae KFAB ESBL (MIC 0.38 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_kfab &lt;- read_excel(\"datasets_single/kp_FAB_caz_avi_powder4-1.xlsx\")\nfitkfab &lt;- drda(tpos ~ ctz_s, data=caz_avi_kfab, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitkfab, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 19: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against KPC- producing K. pneumoniae\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_kfab &lt;- read_excel(\"datasets_single/kp_FAB_caz_avi_powder4-1.xlsx\")\nfitkfab &lt;- drda(tpos ~ ctz_s, data=caz_avi_kfab, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fitkfab, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 17: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n18.54827\n17.58236\n19.51418\n\n\n0.25\n20.74190\n20.01959\n21.46420\n\n\n0.5\n23.19495\n22.00443\n24.38548\n\n\n0.75\n25.93813\n23.96559\n27.91067\n\n\n0.9\n29.00572\n26.27565\n31.73580\n\n\n0.95\n31.29690\n27.87479\n34.71901\n\n\n\n\n\n\n\n\n\n\n\n\n\nK. pneumoniae WT (MIC 0.125 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_wt2 &lt;- read_excel(\"datasets_single/kpwt_caz_avi_powder_4-1.xlsx\")\nfitwt &lt;- drda(tpos ~ ctz_s, data=caz_avi_wt2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitwt, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 20: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against a wt strain\n\n\n\n\n\n\n\nCode\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_wt2 &lt;- read_excel(\"datasets_single/kpwt_caz_avi_powder_4-1.xlsx\")\nfitwt &lt;- drda(tpos ~ ctz_s, data=caz_avi_wt2, mean_function = \"loglogistic4\", max_iter = 1000)\n\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_5 &lt;- read_excel(\"datasets_single/kpwt_caz_avi_powder_4-1.xlsx\")\nfitwt2 &lt;- drda(tpos ~ ctz_s, data=caz_avi_wt2, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fitwt, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 18: Pharmacodynamic estimates K. pneumoniae WT (MIC 0.125 mg/L)\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n4.104039\n3.907545\n4.300533\n\n\n0.25\n4.853535\n4.727647\n4.979422\n\n\n0.5\n5.739906\n5.602824\n5.876987\n\n\n0.75\n6.788149\n6.522560\n7.053738\n\n\n0.9\n8.027827\n7.540413\n8.515241\n\n\n0.95\n8.997963\n8.099929\n9.895996\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nE. coli ATCC 25922 (MIC 0.19 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_ecoli &lt;- read_excel(\"datasets_single/ecoliatcc_caz_avi_powder4-1.xlsx\")\nfitecoli &lt;- drda(tpos ~ ctz_s, data=caz_avi_ecoli, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitecoli, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 21: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against E. coli ATCC 25922 (MIC 0.19 mg/L)\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_ecoli &lt;- read_excel(\"datasets_single/ecoliatcc_caz_avi_powder4-1.xlsx\")\nfitecoli &lt;- drda(tpos ~ ctz_s, data=caz_avi_ecoli, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fitecoli, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 19: Pharmacodynamic estimates for a high-inoculum\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n3.823371\n3.241785\n4.404957\n\n\n0.25\n4.312649\n3.937461\n4.687837\n\n\n0.5\n4.864540\n4.644781\n5.084298\n\n\n0.75\n5.487056\n5.137118\n5.836995\n\n\n0.9\n6.189236\n5.480141\n6.898332\n\n\n0.95\n6.717490\n5.482243\n7.952737\n\n\n\n\n\n\n\n\n\n\n\n\n\nCOMPARISON OF POSSIBLE INDICATOR ISOLATES\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nkpca &lt;- read_excel(\"datasets_single/kpca_caz_avi_powder_4-1.xlsx\")\nkpcb &lt;- read_excel(\"datasets_single/kpcb_caz_avi_powder_4-1.xlsx\")\nkpccatania &lt;- read_excel(\"datasets_single/kpccatania_caz_avi_powder_4-1.xlsx\")\ncaz_avi_kfab &lt;- read_excel(\"datasets_single/kp_FAB_caz_avi_powder4-1.xlsx\")\nkpwt &lt;- read_excel(\"datasets_single/kpwt_caz_avi_powder_4-1.xlsx\")\ncaz_avi_kprad &lt;- read_excel(\"datasets_single/kp_PRAD_caz_avi_powder4-1.xlsx\")\nkpatcc &lt;- read_excel(\"datasets_single/kpatcc_caz_avi_powder4-1.xlsx\")\n\n## fit models for each of the isolates\nfitkpca &lt;- drda(tpos ~ ctz_s, kpca, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkpcatcc &lt;- drda(tpos ~ ctz_s, kpatcc, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkpcb &lt;- drda(tpos ~ ctz_s, kpcb, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkpccatania &lt;- drda(tpos ~ ctz_s, kpccatania, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkpwt &lt;- drda(tpos ~ ctz_s, kpwt, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkfab &lt;- drda(tpos ~ ctz_s, data=caz_avi_kfab, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkprad &lt;- drda(tpos ~ ctz_s, data=caz_avi_kprad, mean_function = \"loglogistic4\", max_iter = 1000)\n## plot all of the isolates together\np &lt;-plot(fitkpwt, fitkfab, fitkprad,  fitkpcatcc, fitkpcb, fitkpca, fitkpccatania, base=\"10\", xlab = \"Ceftazidime-avibactam conc. (mg/L)\", ylab = \"Tpos (hr)\",cex = 0.9, legend_location=\"topleft\", legend = c(\"0.125 mg/L\", \"0.38 mg/L\", \"0.5 mg/L\",  \"0.75 mg/L\", \"1 mg/L\", \"2 mg/L\", \"16 mg/L\")) \n\n\n\n\n\n\n\n\nFigure 22: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\nCONCLUSIONS\nThese data demonstrate that Tpos is a robust PD endpoint and the relationship of ceftazidime/avibactam concentrations versus Tpos follows classical sigmoidal dose response relationship with a steep transitional portion of the dose response curve that occurs near the MIC of the pathogen. Although ED50/90 estimates were broadly similar if the commercial (pharmaceutical) and analytical powder formulations were tested, used of high-fixed concentrations of avibactam or testing at very high K. pneumoniae inocula resulted in broader concentration-effect curves and higher EC50/90 estimates.  \n\n\n\n\nMEROPENEM\n\nK. pneumoniae ATCC (MIC 0.03 mg/L)\n\nThe impact of increasing meropenem concentrations on Tpos observed with the ATCC ESBL producing Klebsiella pneumoniae was tested using similar methodology as previously described\nAnalytical powder was used to produce serum concentration\nAs shown in Figure 23, Tpos increased as meropenem concentrations surpassed the MIC, with an estimated pharmacodynamic parameters consistent with previous experiments that showed transition in the EC50/EC90 at simulated serum concentrations near the MIC as shown in Table 20.\n\n\n\nCode\n## a four-parameter logistic regression model is fit to meropenem concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nmero &lt;- read_excel(\"datasets_single/ATCC_meropenem.xlsx\")\nfit11 &lt;- drda(tpos ~ mero_s, data=mero, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit11, xlab = \"Meropenem serum conc. (mg/L)\", ylab = \"Tpos (hr)\", xlim =c(0,100))\n\n\n\n\n\n\n\n\nFigure 23: Pharmacodynamic relationship of Tpos to meropenem concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nmero &lt;- read_excel(\"datasets_single/ATCC_meropenem.xlsx\")\nfit11 &lt;- drda(tpos ~ mero_s, data=mero, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit11, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 20: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n1.165027\n1.026833\n1.303220\n\n\n0.25\n1.460430\n1.351831\n1.569029\n\n\n0.5\n1.830736\n1.764894\n1.896577\n\n\n0.75\n2.294935\n2.177266\n2.412605\n\n\n0.9\n2.876837\n2.586027\n3.167648\n\n\n0.95\n3.354810\n2.861582\n3.848038\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC B (MIC 32 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to meropenem concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nmero2 &lt;- read_excel(\"datasets_single/KPCB_meropenem.xlsx\")\nfit11 &lt;- drda(tpos ~ mero_s, data=mero2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit11, xlab = \"Meropenem serum conc. (mg/L)\", ylab = \"Tpos (hr)\", xlim =c(0,100))\n\n\n\n\n\n\n\n\nFigure 24: Pharmacodynamic relationship of Tpos to meropenem concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nmero2 &lt;- read_excel(\"datasets_single/KPCB_meropenem.xlsx\")\nfit11 &lt;- drda(tpos ~ mero_s, data=mero2, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit11, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 21: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n39.09324\n38.35251\n39.83397\n\n\n0.25\n40.62838\n40.06818\n41.18857\n\n\n0.5\n42.22380\n41.61877\n42.82882\n\n\n0.75\n43.88187\n43.02567\n44.73807\n\n\n0.9\n45.60505\n44.37855\n46.83155\n\n\n0.95\n46.81557\n45.21113\n48.42000\n\n\n\n\n\n\n\n\n\n\n\n\n\nComparison of ATCC and KPC B isolates\n A comparison of meropenem activity against the ATCC ESBL-producing reference (MIC 0.03 mg/L) and KPC-carbapenemase producing K. pneumoniae isolates are shown in Figure 25. The meropenem EC50 measured by Tpos was 23-fold higher for the KPC-carbapenemase producing isolate versus the the ESBL-producing ATCC isolate. Despite variability in the response was noted for the KPC-B isolate at 20 mg/L and 80 mg/mL concentrations (experiments are currently being repeated), the EC50 were nearly identical (indicated by the dotted lines) when corrected for pathogen MIC. These data suggest that it may be possible to substitute sensitive indicator isolates with low MICs to predict pharmacodynamic responses of isolates with higher MICs.\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nmero2 &lt;- read_excel(\"datasets_single/KPCB_meropenem.xlsx\")\nmero &lt;- read_excel(\"datasets_single/ATCC_meropenem.xlsx\")\nfit4a &lt;- drda(tpos ~ mero, mero, mean_function = \"loglogistic4\", max_iter = 1000)\nfit4b &lt;- drda(tpos ~ mero, mero2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit4a, fit4b, xlab = \"Meropenem conc. (mg/L)\", ylab = \"Tpos\",cex = 0.9,legend = c(\"KP ATCC ESBL\", \"KP KPC_2\"))\n\n\n\n\n\n\n\n\nFigure 25: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\nCONCLUSIONS\nSimilar to ceftazidime-avibactam, experiments with meropenem demonstrated that Tpos is a robust PD endpoint and the relationship of meropenem concentrations versus Tpos follows classical sigmoidal dose response relationship with a steep transitional portion of the dose response curve that occurs near the MIC of the pathogen. \nA key observation is that the pharmacodynamics were similar when meropenem was tested against a highly-susceptible ATCC isolate (MIC 0.03 mg/L) and and the KPC-producing K.pneumoniae B isolate (MIC 32 mg/L) with at proportional difference in the EC50/90. Therefore, it may be possible to use highly-susceptible “indicator” strains for testing to predict activity against more resistant isolates. This is important because direct testing of 1 mL inoculum may routinely result in limited antimicrobial activity measured by Tpos (&lt;10 hours) as dilutional effects when the serum samples is introduced into the bottle containing a total volume of 42 mL will reduce the actual testing concentrations of the antibiotics below the MIC for highly resistant pathogens.   This effect could be counteracted by testing with highly sensitive “indicator” isolates based on the expected serum concentrations of the antibiotic.\n\n\n\n\nGENTAMICIN\n\nKPC A (MIC 2 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to gentamicin concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ngent1 &lt;- read_excel(\"datasets_single/KPCA_gent.xlsx\")\nfit12 &lt;- drda(tpos ~ gent_s, data=gent1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit12, xlab = \"Gentamicin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 26: Pharmacodynamic relationship of Tpos to gentamicin concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ngent1 &lt;- read_excel(\"datasets_single/KPCA_gent.xlsx\")\nfit12 &lt;- drda(tpos ~ gent_s, data=gent1, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit12, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 22: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n56.65250\n53.43037\n59.87462\n\n\n0.25\n62.53591\n60.25523\n64.81660\n\n\n0.5\n69.03033\n67.01957\n71.04109\n\n\n0.75\n76.19920\n73.71019\n78.68821\n\n\n0.9\n84.11256\n79.42354\n88.80158\n\n\n0.95\n89.95932\n78.37830\n101.54033\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC B (MIC 0.5 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to gentamicin concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ngent2 &lt;- read_excel(\"datasets_single/KPCB_gent.xlsx\")\nfit13 &lt;- drda(tpos ~ gent_s, data=gent2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit13, xlab = \"Gentamicin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 27: Pharmacodynamic relationship of Tpos to gentamicin concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ngent2 &lt;- read_excel(\"datasets_single/KPCB_gent.xlsx\")\nfit13 &lt;- drda(tpos ~ gent_s, data=gent2, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit13, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 23: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n18.56332\n16.93133\n20.19530\n\n\n0.25\n19.92766\n19.06150\n20.79382\n\n\n0.5\n21.39227\n20.34817\n22.43636\n\n\n0.75\n22.96452\n20.81244\n25.11660\n\n\n0.9\n24.65233\n21.10862\n28.19605\n\n\n0.95\n25.87062\n20.96263\n30.77861\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCOLISTIN\n\nKPC B (MIC 0.125 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to colistin concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncoli1 &lt;- read_excel(\"datasets_single/KPCB_coli.xlsx\")\nfit14 &lt;- drda(tpos ~ coli_s, data=coli1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit14, xlab = \"Colistin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 28: Pharmacodynamic relationship of Tpos to colistin concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncoli1 &lt;- read_excel(\"datasets_single/KPCB_coli.xlsx\")\nfit14 &lt;- drda(tpos ~ coli_s, data=coli1, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit14, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 24: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n3.814341\n3.374386\n4.254296\n\n\n0.25\n4.696574\n4.395993\n4.997155\n\n\n0.5\n5.782863\n5.463324\n6.102402\n\n\n0.75\n7.120404\n6.500514\n7.740293\n\n\n0.9\n8.767309\n7.696486\n9.838132\n\n\n0.95\n10.100091\n8.130500\n12.069682\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMEROPENEM-VABORBACTAM\n\nKPC B (MIC X mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to meropenem-vaborbactam concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nvabo1 &lt;- read_excel(\"datasets_single/KPCB_vabo.xlsx\")\nfit14 &lt;- drda(tpos ~ vabo_s, data=vabo1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit14, xlab = \"Meropenem-vabobactam serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 29: Pharmacodynamic relationship of Tpos to meropenem-vaborbactam concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nvabo1 &lt;- read_excel(\"datasets_single/KPCB_vabo.xlsx\")\nfit14 &lt;- drda(tpos ~ vabo_s, data=vabo1, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit14, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 25: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n5.391292\n4.092373\n6.690211\n\n\n0.25\n7.797856\n6.671079\n8.924633\n\n\n0.5\n11.278661\n10.098053\n12.459269\n\n\n0.75\n16.313228\n13.817427\n18.809029\n\n\n0.9\n23.595123\n18.006802\n29.183445\n\n\n0.95\n30.327549\n19.089870\n41.565227\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTIGECYCLINE\n\n\n\n\n\n\nImportant\n\n\n\nExperiments performed using freshly collected blood samples that use EDTA as an anticoagulant result in enhanced tigecycline activity as previously reported by Deitchman et al.2 This phenomena was evident in preliminary experiments as shown in Figure 30.\n\n\nCode\nlibrary (readxl)\nlibrary (ggplot2)\ntheme_set(theme_bw())\nedta &lt;- read_excel(\"datasets_single/edtaeffect.xlsx\")\nggplot(edta, aes(x=tig_s, y=tpos, color=tube, shape=tube)) + \n  geom_point(size=4, alpha = 0.7) + \nscale_x_continuous (name=\"Tigecycline conc, mg/L\") +\nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,25)) \n\n\n\n\n\n\n\n\nFigure 30: Effect of tigeycvcline concentrations on Tpos of K. pneumoniae using serum collected with and withouth EDTA\n\n\n\n\n\n\n\n\nKPC-A (MIC 0.75 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to tigecycline concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ntig1 &lt;- read_excel(\"datasets_single/kpca_tig.xlsx\")\nfit15 &lt;- drda(tpos ~ tig_s, data=tig1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit15, xlab = \"Tigecycline serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 31: Pharmacodynamic relationship of Tpos to tigecycline concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ntig1 &lt;- read_excel(\"datasets_single/kpca_tig.xlsx\")\nfit15 &lt;- drda(tpos ~ tig_s, data=tig1, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit15, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 26: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n26.21193\n22.64088\n29.78298\n\n\n0.25\n33.33312\n30.73822\n35.92801\n\n\n0.5\n42.38896\n40.56986\n44.20806\n\n\n0.75\n53.90507\n50.72689\n57.08325\n\n\n0.9\n68.54984\n60.64442\n76.45527\n\n\n0.95\n80.72308\n56.72937\n104.71680\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC-B (MIC 0.38 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to tigecycline concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ntig2 &lt;- read_excel(\"datasets_single/kpcb_tig.xlsx\")\nfit16 &lt;- drda(tpos ~ tig_s, data=tig2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit16, xlab = \"Tigecycline serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 32: Pharmacodynamic relationship of Tpos to tigecycline concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ntig2 &lt;- read_excel(\"datasets_single/kpca_tig.xlsx\")\nfit16 &lt;- drda(tpos ~ tig_s, data=tig2, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit16, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 27: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n26.21193\n22.64088\n29.78298\n\n\n0.25\n33.33312\n30.73822\n35.92801\n\n\n0.5\n42.38896\n40.56986\n44.20806\n\n\n0.75\n53.90507\n50.72689\n57.08325\n\n\n0.9\n68.54984\n60.64442\n76.45527\n\n\n0.95\n80.72308\n56.72937\n104.71680\n\n\n\n\n\n\n\n\n\n\n\n\n\nE. coli ATCC 25922 (MIC 0.125 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to tigecycline concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ntigecoli &lt;- read_excel(\"datasets_single/ecoliatcc_tig.xlsx\")\nfittigecoli &lt;- drda(tpos ~ tig_s, data=tigecoli, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fittigecoli, xlab = \"Tigecycline serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 33: Pharmacodynamic relationship of Tpos to tigecycline concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ntigecoli &lt;- read_excel(\"datasets_single/ecoliatcc_tig.xlsx\")\nfittigecoli &lt;- drda(tpos ~ tig_s, data=tigecoli, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fittigecoli, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 28: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n4.099751\n3.742536\n4.456966\n\n\n0.25\n6.123028\n5.816673\n6.429382\n\n\n0.5\n9.144816\n8.798910\n9.490721\n\n\n0.75\n13.657892\n12.976866\n14.338918\n\n\n0.9\n20.398226\n18.087056\n22.709396\n\n\n0.95\n26.796582\n18.484108\n35.109056\n\n\n\n\n\n\n\n\n\n\n\n\n\nE. coli ATCC 25922 (MIC 0.125 mg/L) protein binding\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nserum &lt;- read_excel(\"datasets_single/ecoliatcc_tig_serum.xlsx\")\npbs &lt;- read_excel(\"datasets_single/ecoliatcc_tig_pbs.xlsx\")\nfitserum &lt;- drda(tpos ~ tig_s, serum, mean_function = \"loglogistic4\", max_iter = 1000)\nfitpbs &lt;- drda(tpos ~ tig_s, pbs, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitserum, fitpbs, xlab = \"Tigecycline conc. (mg/L)\", ylab = \"Tpos\",cex = 0.9,legend = c(\"serum\", \"PBS\"))\n\n\n\n\n\n\n\n\nFigure 34: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nserum &lt;- read_excel(\"datasets_single/ecoliatcc_tig_serum.xlsx\")\npbs &lt;- read_excel(\"datasets_single/ecoliatcc_tig_pbs.xlsx\")\nfitserum &lt;- drda(tpos ~ tig_s, serum, mean_function = \"loglogistic4\", max_iter = 1000)\nfitpbs &lt;- drda(tpos ~ tig_s, pbs, mean_function = \"loglogistic4\", max_iter = 1000)\nedserum&lt;-effective_dose(fitserum, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nedpbs&lt;-effective_dose(fitpbs, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(edserum)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\n\n\n\n\n\n\nEstimate\n\n\nLower .95\n\n\nUpper .95\n\n\n\n\n\n\n0.1\n\n\n2.123423\n\n\n2.085530\n\n\n2.161317\n\n\n\n\n0.25\n\n\n3.333204\n\n\n3.299344\n\n\n3.367064\n\n\n\n\n0.5\n\n\n5.232235\n\n\n5.196848\n\n\n5.267621\n\n\n\n\n0.75\n\n\n8.213202\n\n\n8.144849\n\n\n8.281556\n\n\n\n\n0.9\n\n\n12.892521\n\n\n12.733520\n\n\n13.051522\n\n\n\n\n0.95\n\n\n17.519723\n\n\n17.041417\n\n\n17.998028\n\n\n\n\n\n\nFigure 35: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\nCode\nkbl(edpbs)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\n\n\n\n\n\n\nEstimate\n\n\nLower .95\n\n\nUpper .95\n\n\n\n\n\n\n0.1\n\n\n4.283286\n\n\n3.530962\n\n\n5.035611\n\n\n\n\n0.25\n\n\n6.954032\n\n\n6.402163\n\n\n7.505901\n\n\n\n\n0.5\n\n\n11.290059\n\n\n10.592118\n\n\n11.988000\n\n\n\n\n0.75\n\n\n18.329717\n\n\n17.061603\n\n\n19.597832\n\n\n\n\n0.9\n\n\n29.758793\n\n\n17.553542\n\n\n41.964045\n\n\n\n\n0.95\n\n\n41.376913\n\n\n0.000000\n\n\n90.646797\n\n\n\n\n\n\nFigure 36: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\n\n\nCEFTAZIDIME\n\nK. pneumoniae ATCC 700603 (MIC 12 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nceftaz_atcc &lt;- read_excel(\"datasets_single/kpatcc_ceftazidime.xlsx\")\nfit_ceftazatcc &lt;- drda(tpos ~ ctz_s, data=ceftaz_atcc, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit_ceftazatcc, xlab = \"Ceftazidime serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 37: Pharmacodynamic relationship of Tpos to ceftazidime concentrations against an ESBL producing ATCC strain\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nceftaz_atcc &lt;- read_excel(\"datasets_single/kpatcc_ceftazidime.xlsx\")\nfit_ceftazatcc &lt;- drda(tpos ~ ctz_s, data=ceftaz_atcc, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit_ceftazatcc, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 29: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n245.8990\n206.8423\n284.9557\n\n\n0.25\n295.0812\n265.6254\n324.5370\n\n\n0.5\n354.1003\n335.4615\n372.7390\n\n\n0.75\n424.9237\n398.3337\n451.5137\n\n\n0.9\n509.9125\n446.8074\n573.0176\n\n\n0.95\n577.2350\n434.9467\n719.5233\n\n\n\n\n\n\n\n\n\n\n\n\n\nK. pneumoniae KP-DAM (MIC 4 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nceftaz1 &lt;- read_excel(\"datasets_single/kp_dam_ceftaz.xlsx\")\nfit17 &lt;- drda(tpos ~ ctz_s, data=ceftaz1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit17, xlab = \"Ceftazidime serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 38: Pharmacodynamic relationship of Tpos to ceftazidime concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nceftaz1 &lt;- read_excel(\"datasets_single/kp_dam_ceftaz.xlsx\")\nfit17 &lt;- drda(tpos ~ ctz_s, data=ceftaz1, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fit17, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 30: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n107.0276\n78.27442\n135.7809\n\n\n0.25\n136.4083\n116.29285\n156.5238\n\n\n0.5\n173.8544\n165.49765\n182.2112\n\n\n0.75\n221.5801\n196.00814\n247.1520\n\n\n0.9\n282.4071\n224.19394\n340.6202\n\n\n0.95\n333.0621\n230.10196\n436.0223\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCIPROFLOXACIN\n\nK. pneumoniae WT (MIC &lt;= 0.06)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncipro1 &lt;- read_excel(\"datasets_single/kpwt_cipro_powder.xlsx\")\nfitcipro1 &lt;- drda(tpos ~ cipro_s, data=cipro1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitcipro1, xlab = \"Ciprofloxacin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 39: Pharmacodynamic relationship of Tpos to ceftazidime concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncipro1 &lt;- read_excel(\"datasets_single/kpwt_cipro_powder.xlsx\")\nfitcipro1 &lt;- drda(tpos ~ cipro_s, data=cipro1, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fitcipro1, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 31: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n0.2429975\n0.1876993\n0.2982956\n\n\n0.25\n0.3259756\n0.2760740\n0.3758772\n\n\n0.5\n0.4372888\n0.3916951\n0.4828826\n\n\n0.75\n0.5866130\n0.5247666\n0.6484594\n\n\n0.9\n0.7869281\n0.6566179\n0.9172382\n\n\n0.95\n0.9609705\n0.7089475\n1.2129934\n\n\n\n\n\n\n\n\n\n\n\n\n\nKPC B (MIC &lt;= 0.38)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncipro2 &lt;- read_excel(\"datasets_single/kpcb_cipro_powder.xlsx\")\nfitcipro2 &lt;- drda(tpos ~ cipro_s, data=cipro2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitcipro2, xlab = \"Ciprofloxacin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\n\n\n\nFigure 40: Pharmacodynamic relationship of Tpos to ceftazidime concentrations\n\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncipro2 &lt;- read_excel(\"datasets_single/kpcb_cipro_powder.xlsx\")\nfitcipro2 &lt;- drda(tpos ~ cipro_s, data=cipro2, mean_function = \"loglogistic4\", max_iter = 1000)\ned&lt;-effective_dose(fitcipro2, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%&gt;%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 32: Pharmacodynamic estimates\n\n\n\n\n\n\n\n\nEstimate\nLower .95\nUpper .95\n\n\n\n\n0.1\n7.164090\n6.590145\n7.738036\n\n\n0.25\n8.982345\n8.565516\n9.399174\n\n\n0.5\n11.262075\n10.893533\n11.630618\n\n\n0.75\n14.120404\n13.417518\n14.823290\n\n\n0.9\n17.704179\n16.211318\n19.197041\n\n\n0.95\n20.648354\n17.657499\n23.639209",
    "crumbs": [
      "Workpackage 1-Single Drug"
    ]
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "The Acute Website",
    "section": "",
    "text": "Principal investigator: Irene Zaghi, M.D.1\nSupervisors: Russell E. Lewis, Pharm.D,2 Monica Cricca, M.D., PhD.,1,3 Vittorio Sambri, M.D., PhD.1,3\n1Laboratorio Unico della AUSL della Romagna, in Pievesestina di Cesena, Italy\n2 Department of Molecular Medicine, University of Padua, Padua, Italy\n3 Department of Diagnostic and Experimental Medicine, University of Bologna, Italy\n\nCollaborator:\n\nJason Roberts, Pharm.D., PhD., NHMRC Leadership Fellow, UQ Centre for Clinical Research, Faculty of Medicine, Acting Director, CCR. Faculty of Medicine\n\nFunding:\n\nEuropean Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2022 Research Grants Program\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAdditional support:\nAnalytical grade antibiotic powder for testing provided by:"
  }
]